Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Adipose-Derived MSCs for Inflammaging
NCT05827757Phase 2Unknown
- Sponsor
- DNA International Hospital
- Start
- Apr 2020
- Primary completion
- Apr 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous adipose-derived mesenchymal stromal cells in inflammaging, sponsored by DNA International Hospital. Primary endpoint: The safety and toleration of stem cell infusion at Day 180. Status: unknown.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
inflammaging
Beyond the preview
Go deeper on NCT05827757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05827757.